Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Valeant Pharmaceuticals International



) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.3%. By the end of trading, Valeant Pharmaceuticals International rose $2.05 (2.1%) to $97.85 on light volume. Throughout the day, 797,116 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1,561,800 shares. The stock ranged in a price between $95.28-$98.04 after having opened the day at $95.39 as compared to the previous trading day's close of $95.80. Other companies within the Health Care sector that increased today were:

Astex Pharmaceuticals



), up 24.4%,

GW Pharmaceuticals PLC ADR



), up 17.6%,

Idera Pharmaceuticals



Scroll to Continue

TheStreet Recommends

), up 13.1% and




), up 10.7%.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $33.1 billion and is part of the drugs industry. Shares are up 60.3% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and generally higher debt management risk.

On the negative front,

Rexahn Pharmaceuticals



), down 16.7%,




), down 16.4%,

Prana Biotechnology



), down 12.5% and

Catalyst Pharmaceutical Partners



), down 12.4% , were all laggards within the health care sector with




) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.